Preparing for the clinical development of the TOPK inhibitor OTS964
First written in FY2016. 19 of 20 entries say "Restated". Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1RestatedAnnual report
「In addition, we have identified multiple final compounds targeting TOPK, a novel cancer-specific target molecule important for cell division. As significant results were obtained in animal studies, we are advancing formulation studies and preclinical studies.」
For OTS964, formulation studies and preclinical studies remain ongoing based on multiple final compounds. - FY2025RestatedAnnual report
「In addition, we have identified multiple final compounds targeting TOPK, a novel cancer-specific target molecule important for cell division. As significant results were obtained in animal studies, we are advancing formulation studies and preclinical studies.」
For OTS964, formulation studies and preclinical studies remain ongoing based on multiple final compounds. - FY2023-Q3RestatedAnnual report
「In addition, we have identified multiple final compounds targeting TOPK, a novel cancer-specific target molecule important for cell division. As significant results were obtained in animal studies, we are advancing formulation studies and preclinical studies.」
For OTS964, formulation studies and preclinical studies remain ongoing based on the identification of multiple final compounds. - FY2023-Q1RestatedAnnual report
「In addition, we have identified multiple final compounds targeting TOPK, a novel cancer-specific target molecule important for cell division. As significant results were obtained in animal studies, we are advancing formulation studies and preclinical studies.」
For OTS964, formulation studies and preclinical studies remain ongoing based on the identification of multiple final compounds. - FY2022-Q3RestatedAnnual report
「In addition, we have identified multiple final compounds targeting TOPK, a novel cancer-specific target molecule important for cell division. As significant results were obtained in animal studies, we are advancing formulation studies and preclinical studies.」
For OTS964, formulation studies and preclinical studies remain ongoing based on the identification of multiple final compounds. - FY2022-Q1RestatedAnnual report
「In addition, we have identified multiple final compounds targeting TOPK, a novel cancer-specific target molecule important for cell division. As significant results were obtained in animal studies, we are advancing formulation studies and preclinical studies.」
For OTS964, formulation studies and preclinical studies remain ongoing based on the identification of multiple final compounds. - FY2021-Q3RestatedAnnual report
「In addition, we have identified multiple final compounds targeting TOPK, a novel cancer-specific target molecule important for cell division. As significant results were obtained in animal studies, we are advancing formulation studies and preclinical studies.」
For OTS964, formulation studies and preclinical studies remain ongoing based on the identification of multiple final compounds. - FY2021-Q2RestatedAnnual report
「In addition, we have identified multiple final compounds targeting TOPK, a novel cancer-specific target molecule important for cell division. As significant results were obtained in animal studies, we are advancing formulation studies and preclinical studies.」
For OTS964, formulation studies and preclinical studies remain ongoing based on the identification of multiple final compounds. - FY2021-Q1RestatedAnnual report
「In addition, we have identified multiple final compounds targeting TOPK, a novel cancer-specific target molecule important for cell division. As significant results were obtained in animal studies, we are advancing formulation studies and preclinical studies.」
For OTS964, formulation studies and preclinical studies remain ongoing based on the identification of multiple final compounds. - FY2020-Q3RestatedAnnual report
「In addition, we have identified multiple final compounds targeting TOPK, a novel cancer-specific target molecule important for cell division. As significant results were obtained in animal studies, we are advancing formulation studies and preclinical studies.」
For OTS964, formulation studies and preclinical studies remain ongoing based on the identification of multiple final compounds. - FY2020-Q2RestatedAnnual report
「In addition, we have identified multiple final compounds targeting TOPK, a novel cancer-specific target molecule important for cell division. As significant results were obtained in animal studies, we are advancing formulation studies and preclinical studies.」
For OTS964, formulation studies and preclinical studies remain ongoing based on the identification of multiple final compounds. - FY2020-Q1RestatedAnnual report
「In addition, we have identified multiple final compounds targeting TOPK, a novel cancer-specific target molecule important for cell division. As significant results were obtained in animal studies, we are advancing formulation studies and preclinical studies.」
For OTS964, formulation studies and preclinical studies remain ongoing based on the identification of multiple final compounds. - FY2018RestatedAnnual report
「In addition, we have identified multiple final compounds targeting TOPK, a novel cancer-specific target molecule important for cell division. As significant results were obtained in animal studies, we are advancing formulation studies and preclinical studies.」
For OTS964, formulation studies and preclinical studies in preparation for the start of clinical trials remain ongoing, based on the identification of a final compound. - FY2018-Q3RestatedAnnual report
「We have identified a final compound targeting TOPK, a novel cancer-specific target molecule important for cell division. As significant results, including tumor disappearance, were obtained in animal studies, we are advancing formulation studies and preclinical studies with the aim of beginning clinical trials.」
For OTS964, formulation studies and preclinical studies for the start of clinical trials remain ongoing. - FY2018-Q2RestatedAnnual report
「We have identified a final compound targeting TOPK, a novel cancer-specific target molecule important for cell division. As significant results, including tumor disappearance, were obtained in animal studies, we are advancing formulation studies and preclinical studies with the aim of beginning clinical trials.」
For OTS964, formulation studies and preclinical studies for the start of clinical trials remain ongoing. - FY2017RestatedAnnual report
「We are advancing formulation studies and preclinical studies with the aim of beginning clinical trials. TOPK inhibitor OTS964 has been selected for the National Cancer Institute's NCL characterization program, a program for characterizing and evaluating the safety of candidate cancer drug compounds.」
For OTS964, the company continues to report formulation studies, preclinical studies, and selection for the NCL program in preparation for the start of clinical trials. - FY2017-Q3RestatedAnnual report
「We are advancing formulation studies and preclinical studies with the aim of beginning clinical trials. TOPK inhibitor OTS964 has been selected for the National Cancer Institute's NCL characterization program, and this is expected to accelerate preclinical development of the compound.」
For OTS964, formulation studies and preclinical studies for the start of clinical trials remain ongoing. - FY2017-Q2RestatedAnnual report
「We are advancing formulation studies and preclinical studies with the aim of beginning clinical trials. TOPK inhibitor OTS964 has been selected for the National Cancer Institute's NCL characterization program, and this is expected to accelerate preclinical development of the compound.」
Formulation studies and preclinical studies for the start of clinical trials of OTS964 remain ongoing. - FY2017-Q1RestatedAnnual report
「We are advancing formulation studies and preclinical studies with the aim of beginning clinical trials. TOPK inhibitor OTS964 has been selected for the National Cancer Institute's NCL characterization program, a program for characterizing and evaluating the safety of candidate cancer drug compounds.」
Preparation of formulation studies and preclinical studies for the start of clinical trials of OTS964 remains ongoing. - FY2016First statedAnnual report
「We are advancing formulation studies and preclinical studies with the aim of beginning clinical trials. TOPK inhibitor OTS964 has been selected for the National Cancer Institute's NCL characterization program, a program for characterizing and evaluating the safety of candidate cancer drug compounds.」
Based on identification of the final compound, the results of animal studies, and selection for the NCL program, the compound is in the preparation stage for the start of clinical trials.